Company Filing History:
Years Active: 2009-2010
Title: Innovations by Bomie Han: Pioneering Anti-myostatin Antibodies
Introduction
Bomie Han, an accomplished inventor located in Carmel, IN, has made significant contributions to the field of biotechnology with his innovative patents. With a focus on developing anti-myostatin antibodies, Han's work aims to enhance muscle mass and bone density, offering potential treatments for various disorders in both mammalian and avian species.
Latest Patents
Han holds two patents, with his latest inventions centered around anti-myostatin antibodies. These antibodies identify and bind to a neutralizing epitope located within amino acids 40-64 of the mature form of human myostatin. His unique approach ensures high-affinity binding to GDF-8 over GDF-11 and includes potential formulations as chimeric, humanized, or fully human antibodies. Additionally, these innovations can be developed into immunoconjugates or antigen-binding fragments, making them versatile tools in medical treatments.
Career Highlights
Bomie Han is currently associated with Eli Lilly and Company, where he leverages his expertise in biotechnology to drive innovation and research. His contributions to the field have positioned him as a key figure in the development of advanced therapeutic agents.
Collaborations
During his career at Eli Lilly and Company, Han has collaborated with talented coworkers, including Andrew Ihor Korytko and Pamela Jean Mitchell. These partnerships reflect a dynamic work environment conducive to innovation and progress in the realm of biotechnology.
Conclusion
Bomie Han's advancements in anti-myostatin antibodies underline his role as an influential inventor in the biopharmaceutical industry. His dedication to enhancing treatment options for muscle and bone disorders demonstrates the potential of his innovations to improve health outcomes for diverse species.